A 2024 study examining weight loss plateaus observed that, for subjects taking semaglutide, weight loss began to plateau after 15 months
On average, there was no significant regain at four weeks versus controls, indicating early weight loss was largely maintained at that point
Data suggest GLP-1s help clear toxic proteins, reduce inflammation, improve brain energy use, and protect cell connections
This set just makes it easy to be sure
In vivo, retatrutide produced significant reductions in body weight, adiposity, and blood glucose levels in diet-induced obese mouse models, outperforming dual GIP/GLP-1 agonists through the additional thermogenic and energy-expenditure effects mediated by glucagon receptor activation